The Role of Clopidogrel Resistance-related Genetic and Epigenetic Factors in Major Adverse Cardiovascular Events Among Patients with Acute Coronary Syndrome After Percutaneous Coronary Intervention

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2023 Feb 27

PMID 36843628

Authors

Astuti Giantini

Ina S Timan

Rahajuningsih Dharma

Renan Sukmawan

Rianto Setiabudy

Idrus Alwi

Alida R Harahap

Erlin Listiyaningsih

Lia G Partakusuma

Arif R Tansir

Windy Sahar

Rakhmad Hidayat

Affiliations

Soon will be listed here.

Abstract

Despite patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel therapy, some patients still experience major adverse cardiovascular events (MACEs). Clopidogrel resistance, which may be regulated by genetic and epigenetic factors, may play a role in MACEs. This study aimed to determine the association between genetic ( and polymorphisms) and epigenetic (DNA methylation of and and miRNA-26a expression) factors and their effects on MACEs among post-PCI patients. Post-PCI patients who received a standard dosage of clopidogrel at Harapan Kita Hospital between September 2018 and June 2020 were included in this study. MACEs were observed in patients within 1 year after PCI. Platelet aggregation was assessed using light transmission aggregometry (LTA). DNA methylation of and was assessed using the bisulfite conversion method. and polymorphisms and miRNA-26a expression were evaluated using quantitative real-time polymerase chain reaction (qRT-PCR). Among a total of 201 subjects, 49.8% were clopidogrel-resistant, and 14.9% experienced MACEs within 1 year after PCI (death was 7.5%). Hypomethylation of ( = 0.037) and miRNA-26a upregulation ( = 0.020) were associated with clopidogrel resistance. CYP2C192/3 polymorphisms ( = 0.047) were associated with MACEs in 1 year. This study demonstrated that hypomethylation of and miRNA-26a upregulation increased the risk of clopidogrel resistance in post-PCI patients, but there was no correlation between clopidogrel resistance and MACEs. However, CYP2C192/3 polymorphisms were the factors that predicted MACEs within 1 year.

Citing Articles

In Vitro Analysis of AKR1D1 Interactions with Clopidogrel: Effects on Enzyme Activity and Gene Expression.

Shutevska K, Kadifkova P, Zhivikj Z, Kapedanovska N Balkan J Med Genet. 2025; 27(2):69-75.

PMID: 40070864 PMC: 11892939. DOI: 10.2478/bjmg-2024-0012.

Association of P2RY12 Gene Variants and Non-Genetic Factors With Clopidogrel Responsiveness in Vietnamese Patients After Percutaneous Coronary Intervention: A Cross-Sectional Study.

Ta Anh H, Nguyen Duy T, Bui Duc T, Hoang Van T, Nguyen Oanh O, Luong Cong T J Clin Lab Anal. 2025; 39(5):e70003.

PMID: 39927599 PMC: 11904810. DOI: 10.1002/jcla.70003.

Demographic diversity in platelet function and response to antiplatelet therapy.

Jain K, Tyagi T, Gu S, Faustino E, Hwa J Trends Pharmacol Sci. 2024; 46(1):78-93.

PMID: 39672782 PMC: 11710996. DOI: 10.1016/j.tips.2024.11.005.

The association between abcb1 gene polymorphism and clopidogrel response variability in stroke ischemic: a cross sectional study.

Hidayat R, Nabilah R, Fisher M, Aninditha T, Kurniawan M, Estiasari R BMC Neurol. 2024; 24(1):216.

PMID: 38914966 PMC: 11194867. DOI: 10.1186/s12883-024-03723-y.

Molecular genomic and epigenomic characteristics related to aspirin and clopidogrel resistance.

Kim J, Shin B, Kim D, Shin D, Ahn S, Kim J BMC Med Genomics. 2024; 17(1):166.

PMID: 38902747 PMC: 11188263. DOI: 10.1186/s12920-024-01936-1.

References

Haji Aghajani M, Kobarfard F, Shojaei S, Ahmadpour F, Safi O, Kazemina N . The Impact of Clopidogrel Resistance on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention. Iran J Pharm Res. 2018; 17(3):1099-1104. PMC: 6094421. View

Kar R, Meena A, Yadav B, Yadav R, Kar S, Saxena R . Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. Platelets. 2012; 24(4):297-302. DOI: 10.3109/09537104.2012.693992. View

Shenker N, Flanagan J . Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br J Cancer. 2011; 106(2):248-53. PMC: 3261681. DOI: 10.1038/bjc.2011.550. View

Collet J, Hulot J, Pena A, Villard E, Esteve J, Silvain J . Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2008; 373(9660):309-17. DOI: 10.1016/S0140-6736(08)61845-0. View

Li M, Wang H, Xuan L, Shi X, Zhou T, Zhang N . Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. Medicine (Baltimore). 2017; 96(14):e6553. PMC: 5411211. DOI: 10.1097/MD.0000000000006553. View

Nakanishi R, Berman D, Budoff M, Gransar H, Achenbach S, Al-Mallah M . Current but not past smoking increases the risk of cardiac events: insights from coronary computed tomographic angiography. Eur Heart J. 2015; 36(17):1031-40. PMC: 4416139. DOI: 10.1093/eurheartj/ehv013. View

Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le J . High density DNA methylation array with single CpG site resolution. Genomics. 2011; 98(4):288-95. DOI: 10.1016/j.ygeno.2011.07.007. View

Shahabi P, Siest G, Meyer U, Visvikis-Siest S . Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. Pharmacol Ther. 2014; 144(2):134-61. DOI: 10.1016/j.pharmthera.2014.05.011. View

Lopez Farre A, Tamargo J, Mateos-Caceres P, Azcona L, Macaya C . Old and new molecular mechanisms associated with platelet resistance to antithrombotics. Pharm Res. 2010; 27(11):2365-73. DOI: 10.1007/s11095-010-0209-4. View

10.

Angiolillo D, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E . Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res. 2005; 116(6):491-7. DOI: 10.1016/j.thromres.2005.03.001. View

11.

Feher G, Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B . Clinical importance of aspirin and clopidogrel resistance. World J Cardiol. 2010; 2(7):171-86. PMC: 2998916. DOI: 10.4330/wjc.v2.i7.171. View

12.

Sukmawan R, Hoetama E, Danny S, Giantini A, Listiyaningsih E, Rejeki V . Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Pharmacol Res Perspect. 2021; 9(2):e00738. PMC: 7915409. DOI: 10.1002/prp2.738. View

13.

Amin A, Sheau Chin L, Mohamed Noor D, Mostafa H, S K Abdul Kader M, Kah Hay Y . The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients. Thromb Res. 2017; 158:22-24. DOI: 10.1016/j.thromres.2017.07.032. View

14.

Shaul O . How introns enhance gene expression. Int J Biochem Cell Biol. 2017; 91(Pt B):145-155. DOI: 10.1016/j.biocel.2017.06.016. View

15.

Tang X, Ge L, Chen Z, Kong S, Liu W, Xu Y . Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Drug Metab Dispos. 2016; 44(10):1643-52. DOI: 10.1124/dmd.116.070243. View

16.

Rai M, Seip R, Gupta A, McKay R, Hirst J, Thompson P . CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance. Conn Med. 2012; 76(5):267-72. View

17.

Cui G, Zhang S, Zou J, Chen Y, Chen H . P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: A meta-analysis and review of the literature. Adv Clin Exp Med. 2017; 26(2):343-349. DOI: 10.17219/acem/63745. View

18.

Berezikov E, Cuppen E, Plasterk R . Approaches to microRNA discovery. Nat Genet. 2006; 38 Suppl:S2-7. DOI: 10.1038/ng1794. View

19.

Su Q, Li J, Tang Z, Yang S, Xing G, Liu T . Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China. Med Sci Monit. 2019; 25:7138-7148. PMC: 6775793. DOI: 10.12659/MSM.915971. View

20.

Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange P . ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost. 2007; 98(4):838-43. View